← Back to Search

Anti-metabolite

Nitrocamptothecin vs Gemcitabine for Pancreatic Cancer

Phase 3

Waitlist Available

Research Sponsored by Astex Pharmaceuticals, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Hepatic: SGOT and SGPT no greater than 3 times normal (5 times normal if liver tumor present), Bilirubin no greater than 2.0 mg/dL

Renal: Creatinine no greater than 2.0 mg/dL

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will compare nitrocamptothecin with gemcitabine to see which is more effective in treating pancreatic cancer.

Who is the study for?

Adults with advanced pancreatic cancer that can't be surgically removed may join this trial. They should not have had previous chemotherapy, except for fluorouracil as a radiosensitizer. Participants need to have normal organ function and cannot be pregnant or nursing. Effective contraception is required for fertile participants.Check my eligibility

What is being tested?

This phase III trial compares two chemotherapy drugs: nitrocamptothecin and gemcitabine, to see which one is more effective in treating advanced pancreatic cancer. Patients are randomly assigned to receive either drug.See study design

What are the potential side effects?

Chemotherapy drugs like nitrocamptothecin and gemcitabine can cause side effects such as nausea, vomiting, fatigue, low blood cell counts leading to increased infection risk, liver issues, and potential allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My liver function tests are within the required limits.

Select...

My creatinine level is 2.0 mg/dL or lower.

Select...

I am over 18 years old.

Select...

I can perform most of my daily activities without assistance.

Select...

My pancreatic cancer is advanced and cannot be removed by surgery.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Astex Pharmaceuticals, Inc.Lead Sponsor

95 Previous Clinical Trials

7,961 Total Patients Enrolled

Lawrence A. Romel, MSStudy ChairAstex Pharmaceuticals, Inc.

2 Previous Clinical Trials

Media Library

Gemcitabine (Anti-metabolite) Clinical Trial Eligibility Overview. Trial Name: NCT00005869 — Phase 3

Pancreatic Cancer Research Study Groups:

Pancreatic Cancer Clinical Trial 2023: Gemcitabine Highlights & Side Effects. Trial Name: NCT00005869 — Phase 3

Gemcitabine (Anti-metabolite) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00005869 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the potential risks of this treatment for patients?

"There is some evidence from earlier trials to support the efficacy of this treatment, as well as multiple rounds of data supporting safety. Consequently, our team has given it a score of 3 for safety."

Answered by AI

Can people with the qualifying condition still enroll in this research?

"Unfortunately, this particular trial is not seeking new participants at the moment. However, there are 725 other clinical trials with open recruitment currently underway."

Answered by AI